Metformin inhibits 17β-estradiol-induced epithelial-tomesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKa signaling in endometrial adenocarcinoma cells

Oncotarget

Volumn 7, Issue 16, 2016, Pages 21315-21331

  Liu, Zhao ^a   Qi, Shasha ^a   Zhao, Xingbo ^a   Li, Mingjiang ^a   Ding, Sentai ^a   Lu, Jiaju ^a   Zhang, Hui ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

17 estradiol; Endometrial adenocarcinoma; Epithelial mesenchymal transition; Metformin; Klotho

Indexed keywords

AMP ACTIVATED PROTEIN KINASE ALPHA; BETA KLOTHO PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KLOTHO PROTEIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ESTROGEN; KLB PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PRKAA1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MIGRATION INHIBITION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; CELL MOTION; DRUG EFFECTS; ENDOMETRIUM; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE;

ADENOCARCINOMA; ADULT; AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; BIOMARKERS, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; EPITHELIAL-MESENCHYMAL TRANSITION; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; MEMBRANE PROTEINS; METFORMIN; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84965059989     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7040     Document Type: Article

References (51)

1. Siegel R, Ma J, Zou Z, and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
2. Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, and Plaxe SC. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012; 126:176-179.
3. Katkoori VR, Basson MD, Bond VC, Manne U, and Bumpers HL. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial to mesenchymal transition in colon and breast cancers. Oncotarget. 2015; 6:27763-27777. doi: 10.18632/oncotarget.4615.
4. Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukacišin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, and Kang Y. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol. 2012; 14:1212-1222.
5. Thiery JP, Acloque H, Huang RYJ, and Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139:871-890.
6. Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shrover KR, Horwitz KB, Broaddus RR, and Richer JK. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol. 2008; 21:912-923.
7. Lee JM, Dedhar S, Kalluri R, and Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006; 172:973-981.
8. Maeda M, Johnson KR, and Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci. 2005; 118:873-887.
9. Voulari A, and Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009; 1796: 75-90.
10. Zeisberg M, and Neilson EG. Biomarkers for epithelialmesenchymal transitions. J Clin Invest. 2009; 119:1429-1437.
11. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem. 2003; 278: 21113-21123.
12. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, and O'Regan RM. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-tomesenchymal transition in human prostate cancer cells. Cancer Res. 2008; 68:2479-2488.
13. Mell LK, Meyer JJ, Tretiakova M, Tretiakova M, Khramtsov A, Gong C, Yamada SD, Montag AG, and Mundt AJ. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004; 10:5546-5553.
14. Stefansson IM, Salvesen HB, and Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol. 2004; 22:1242-1252.
15. Kim Y S, Hwang K A, Hyun S H, Nam K H, Lee C K, and Choi K C. Bisphenol A and Nonylphenol Have the Potential to Stimulate the Migration of Ovarian Cancer Cells by Inducing Epithelial-Mesenchymal Transition via an Estrogen Receptor Dependent Pathway. Chem Res Toxicol. 2015; 28:662-671.
16. Wang KH, Kao AP, Lin TC, Chang CC, and Kuo TC. Promotion of epithelial-mesenchymal transition and tumor growth by 17β-estradiol in an ER+/HER2+ cell line derived from human breast epithelial stem cells. Biotechnol Appl Biochem. 2012; 59:262-267.
17. Mak P, Leav I, Pursell B, Bae D, Yang X, Taqlienti CA, Gouvin LM, Sharma VM, and Mercurio AM. ERbeta impedes prostate cancer EMT by destabilizing HIF-1a and inhibitingVEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer cell. 2010; 17:319-332.
18. Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, Yang Y, Liu N, Zhao X, Santin AD, Taylor H, and Huang Y. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene. 2015; 34:3076-3084.
19. Tan BK, Adya R, Chen J, Lehnert H, Sant Cassia LJ, and Randeva HS. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab. 2010; 96:808-816.
20. Takahashi A, Kimura F, Yamanaka A, Takebayashi A, Kita N, Takahashi K, and Murakami T. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int. 2014; 14:53.
21. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, and Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33:1674-1685.
22. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, and Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012; 122:253-270.
23. Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RF, Fortes ZB, and Khaper N. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PloS One. 2014; 9:e98207.
24. Qu C, Zhang W, Zheng G, Zhang Z, Yin J, and He Z. Metformin reverses multidrug resistance and epithelialmesenchymal transition (EMT) via activating AMPactivated protein kinase (AMPK) in human breast cancer cells. Mol and Cellular Biochem. 2014; 386:63-71.
25. Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, Li K, Chen H, Sun F, Yang Z, Jiang J, and He Y. Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal. Clin Cancer Res. 2014; 20:2714-2726.
26. Berg A, Hoivik E A, Mjøs S, Holst F, Werner HM, Tangen IL, Taylor-Weiner A, Gibson WJ, Kusonmano K, Wik E, Trovik J, Halle MK, Øyan AM, Kalland KH, Cherniack AD, Beroukhim R, Stefansson I, Mills GB, Krakstad C, and Salvesen HB. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget. 2015; 6:1327-1339. doi: 10.18632/oncotarget.2675.
27. Friberg E, Orsini N, Mantzoros CS, and Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007; 50:1365-1374.
28. Pernicova I, and Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014; 10:143-156.
29. Rizos CV, and Elisaf MS. Metformin and cancer. Eur J Pharmacol. 2013; 705:96-108.
30. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, and Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013; 8:e71583.
31. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA, and Bae-Jump V. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 2014; 132:438-442.
32. Yu L, Shi, J, Cheng S, Zhu Y, Zhao X, Yang K, Du X, Klocker H, Yang X, and Zhang J. Estrogen promotes prostate cancer cell migration via paracrine release of ENO1 from stromal cells. Mol Endocrinol. 2012; 26:1521-1530.
33. Saha Roy S, and Vadlamudi RK. Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer. 2012; 2012:654698.
34. Ding JX, Feng YJ, Yao LQ, Yu M, Jin HY, and Yin LH. The reinforcement of invasion in epithelial ovarian cancer cells by 17β-Estradiol is associated with up-regulation of Snail. Gynecol Oncol. 2006; 103:623-630.
35. Chen YJ, Li HY, Huang CH, Twu NF, Yen MS, Wang PH, Chou TY, Liu YN, Chao KC, and Yang MH. Oestrogeninduced epithelial-mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis. J Pathol. 2010; 222:261-270.
36. Hardiman P, Pillay OC, and Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003; 361:1810-1812.
37. Arem H, Park Y, Pelser C, Ballard-Barbash R, Irwin ML, Hollenbeck A, Gierach GL, Brinton LA, Pfeiffer RM, and Matthews CE. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. J Natl Cancer Inst. 2013; 105:342-349.
38. Wik E, Ræder M B, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelgvist M, Stefansson IM, Ovan AM, Kalland KH, Akslen LA, and Salvesen HB. Lack of estrogen receptor-a is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res. 2013; 19:1094-1105.
39. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, and Menendez JA. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle. 2010; 9:4461-4468.
40. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, and Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol. 2010; 116:92-98.
41. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, and Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001; 22:153-183.
42. Virtakoivu R, Mai A, Mattila E, De Franceschi N, Imanishi SY, Corthals G, Kaukonen R, Saari M, Cheng F, Torvaldson E, Kosma VM, Mannermaa A, Muharram G, Gilles C, Eriksson J, Soini Y, Lorens JB, and Ivaska J. Vimentin-ERK signaling uncouples Slug gene regulatory function. Cancer Res. 2015; 75:2349-2362.
43. Ichikawa K, Kubota Y, Nakamura T, Weng JS, Tomida T, Saito H, and Takekawa M. MCRIP1, an ERK Substrate, Mediates ERK-Induced Gene Silencing during Epithelial-Mesenchymal Transition by Regulating the Co-Repressor CtBP. Mol Cell. 2015; 58:35-46.
44. Zhang H, Guo Q, Wang C, Yan L, Fu Y, Fan M, Zhao X, and Li M. Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17β-estrodial-induced cell growth in endometrial adenocarcinoma cell. Mol Cell Endocrinol. 2013; 376:60-69.
45. Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, Fujimori T, and Nabeshima YI. Molecular cloning and expression analyses of mouse βklotho, which encodes a novel Klotho family protein. Mech Dev. 2000; 98:115-119.
46. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, and Kuro-o M. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007; 282:26687-26695.
47. Kurosu H, and Kuro-o M. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol. 2009; 299:72-78.
48. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, and Kurzrock R. The FGFR landscape in cancer: analysis of 4853 tumors by next generation sequencing. Clin Cancer Res. 2015; Sep 15 [Epub ahead of print].
49. Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, and Kristeleit R. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol. 2015; 16:686-694.
50. Queiroz E A I F, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RF, Fortes ZB, and Khaper N. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PloS One. 2014; 9:e98207.
51. Zhang H, Li M, Zheng X, Sun Y, Wen Z, and Zhao X. Endometriotic stromal cells lose the ability to regulate cellsurvival signaling in endometrial epithelial cells in vitro. Mol Hum Reprod. 2009; 15:653-663.